๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A clinical experience with the NCGT graft

โœ Scribed by Reddy, K. ;Haque, S. N. ;Cohen, L. ;Sophie, Z. ;Feller, J. ;Stillman, R. M. ;Fitzgerald, J. ;Stanczewski, B. ;Sawyer, P. N.


Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
368 KB
Volume
15
Category
Article
ISSN
0021-9304

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

A comparison of 130 grafts done in 101 patients included 47 veins, 25 Johnson & Johnson dialdehydeโ€starchโ€tanned collagen prostheses, and 58 NCGT grafts that had been followed for a 40โ€month period. This study had documented the fact that in spite of frequent poor runoff, a useful result is provided by the NCGT graft apparently due in part to its builtโ€in nonthrombogenic structure providing a cumulative patency of 73%. The patency rate was even superior with venous bypasses. Therefore, we still feel that the autogenous vein provides the most useful bypass conduit available in vascular reconstruction. In situations where a vein could not be used or was not available the NCGT graft offers an equally useful nonthrombogenic surface to maintain prolonged patency. Thus, collagen appropriately modified can provide a useful prosthesis in vascular reconstruction.


๐Ÿ“œ SIMILAR VOLUMES


Early clinical experience with the impla
โœ Clemens von Birgelen; Michael Haude; Jรถrg Herrmann; Christoph Altmann; Wolfgang ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 196 KB ๐Ÿ‘ 2 views

Coating stents with autologous venous grafts has been suggested to prevent problems associated with conventional stenting, but the need for surgical vessel harvest hampered broad application. A novel synthetic coronary stent graft (CSG) overcomes this limitation by a synthetic membrane, fixed betwee

Clinical experience with the micronucleu
โœ Dr. Harinder S. Garewal; Lois Ramsey; George Kaugars; Jay Boyle ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 616 KB

Because of the logistical and practical problems that make cancer prevention trials using cancer incidence as an endpoint virtually impossible to conduct for the majority of cancer types, there is a desperate need for valid intermediate markers of cancer risk to serve as surrogate endpoints in chemo

Clinical experiences with a CT-simulator
โœ J.M. Galvin; W. Powlis; A. Turrisi; E. Cheng; R.L. Goodman ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 230 KB